Terns Starts US Trial of Lead Drug, a NASH Candidate
June 13, 2019 at 06:40 AM EDT
Terns Pharma, a Silicon Valley-Shanghai company, started a US Phase I clinical trial of TERN-101 to treat non-alcoholic steatohepatitis (NASH). TERN-101 is a farnesoid X receptor (FXR) agonist. One year ago, Terns in-licensed three drug candidates from Eli Lilly, including TERN-101. At the same time, the company announced it had received $30 million in start-up capital from Lilly Asia Ventures. Terns focuses on molecularly-targeted drugs and combination therapies that treat liver diseases and liver cancer. More details.... Stock Symbol: (NYSE: LLY) Share this with colleagues: // //